Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.15 USD | -1.81% |
|
-4.79% | -15.98% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- With an expected P/E ratio at 107.14 and 48.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.38 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.98% | 749M | - | ||
+18.69% | 3,317B | C+ | ||
+20.47% | 95.04B | B | ||
+19.87% | 89.51B | B+ | ||
+50.38% | 57.5B | D+ | ||
-20.47% | 49.11B | B+ | ||
+37.92% | 48.55B | D+ | ||
+88.35% | 43.81B | D+ | ||
-35.60% | 39.87B | B- | ||
-3.47% | 27.19B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ENFN Stock
- Ratings Enfusion, Inc.